Iradimed Corp. (IRMD) Tops Q4 EPS by 12c; Guides Above

Iradimed Corp. (NASDAQ: IRMD) reported Q4 EPS of $0.33, $0.12 better than the analyst estimate of $0.21. Revenue for the quarter came in at $11.9 million versus the consensus estimate of $11.63 million.

GUIDANCE:

Iradimed Corp. sees Q1 2022 EPS of $0.20-$0.21. Iradimed Corp. sees Q1 2022 revenue of $12.1-12.1 million, versus the consensus of $11.07 million.

Iradimed Corp. sees FY2022 EPS of $0.91-$1.01, versus the consensus of $0.83. Iradimed Corp. sees FY2022 revenue of $51.4-52.2 million, versus the consensus of $45.62 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.

You May Also Be Interested In

• Lemaitre Vascular (LMAT) Misses Q3 EPS by 4c ; Offers Guidance
• biote Corp. (BTMD) Misses Q3 EPS by 1c ; Offers Guidance
• Cytek Biosciences, Inc. (CTKB) Tops Q3 EPS by 1c ; Offers Guidance